2020 Virtual Mini Symposia Schedule

HomeMembersAssemblies and SectionsAbout2020 Virtual Mini Symposia Schedule ▶ CP - B16 and D13 - Interstitial Lung Disease: Prognosis, Biomarkers and Treatment
CP - B16 and D13 - Interstitial Lung Disease: Prognosis, Biomarkers and Treatment

 Date: Thursday, 5 November 2020 

<Back to Mini Symposia Main Page

Maryl Kreider, Jennifer Taylor-Cousar and Jessica Bon 
Past, Present, and Incoming CP Program Committee Chairs 

Moderated By: Rupal Shah, MD, MSCE, Julie Morisset, MD and Chad Newton, MD 

  • Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis (IPF): A Retrospective, Pooled Analysis from Ascend, Capacity, and Inspire – Michael Kreuter, MD 

  • The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-Trimoxazole - A Randomised Controlled Trial – Andrew Wilson, MD FRCP 

  • Effects of Nintedanib in Subgroups Based on Combined Pulmonary Fibrosis and Emphysema (CPFE) Index at Baseline – Vincent Cottin, MD 

  • Efficacy and Safety of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH) – Juergen Behr, MD 

  • A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension (PH) Associated with Fibrotic Interstitial Lung Disease (fILD) on Long Term Oxygen Therapy – Steven Nathan, MD 

  • Relationship of Baseline Measures to the Change in the Forced Vital Capacity in a Phase 3 Randomized Controlled Trial of Tocilizumab for the Treatment of Early Systemic Sclerosis – Dinesh Khanna, MD, MS 

  • Inhaled GM-CSF (Molgramostim) Therapy Reduces the Need for Whole Lung Lavage in Patients with Autoimmune Pulmonary Alveolar Proteinosis - Long-Term Results from a Randomized, Double-Blind Trial (IMPALA) – Bruce Trapnell, MD 

  • Anti-Fibrotic Therapy Modulates Mortality Risk Associated with Circulating Plasma Biomarkers in Patients with Idiopathic Pulmonary Fibrosis – Justin Oldham, MD MS

  • Association of Circulating Proteins with Death or Lung Transplant in the IPF-PRO Registry Cohort – Jamie Todd, MD 

  • Extracellular Matrix Biomarkers Predict Lung Function and Rate of Decline in Pulmonary Sarcoidosis – Gillian Goobie, MD  

  • Single Cell RNA Sequencing of Peripheral Blood Mononuclear Cells in Idiopathic Pulmonary Fibrosis Reveals the Cellular Origin of the Outcome Predictive 52-Gene Signature – Avraham Unterman, MD, MBA